Key result
Among echogenic nonshadowing renal lesions >4 mm found at ultrasound, 62.0% were angiomyolipomas and 5.1% were renal cell carcinomas, indicating follow-up is necessary to avoid missing cancer.
Why the study?
What percentage of echogenic nonshadowing renal lesions >4 mm on ultrasound are angiomyolipomas, and what is the utility of MRI for diagnosis?
Observational (n=132)
No
What percentage of echogenic nonshadowing renal lesions >4 mm on ultrasound are angiomyolipomas, and what is the utility of MRI for diagnosis?
Echogenic nonshadowing renal lesions >4 mm on ultrasound should not be assumed to be AMLs without follow-up, as 5.1% are renal cell carcinomas.
Answers are grounded in this paper and cite their sources.
May support follow-up imaging to exclude malignancy; leaves open optimal protocols and MRI utility pending prospective validation.
OBJECTIVE: The purpose of this study is to evaluate what percentage of echogenic nonshadowing renal lesions larger than 4 mm found at ultrasound are angiomyolipomas (AMLs) and to review how to diagnose AMLs, with particular emphasis on the increasing role played by MRI. MATERIALS AND METHODS: The study data were obtained at a single institution over a period of 45 months. Although some patients were being reviewed for specific symptoms, such as hematuria, pain, or recurrent urinary tract infections, most of the findings were incidental. Follow-up data on 158 lesions in 132 patients were available. Confirmation of diagnosis was made with follow-up imaging or with histopathologic examination. RESULTS: Ninety-eight (62.0%) of the lesions were AMLs, eight (5.1%) were renal cell carcinomas, three (1.9%) were oncocytomas, 17 (10.8%) were artifacts, seven (4.4%) were fat, five (3.2%) were calculi, another eight (5.1%) were scars, and 12 (7.6%) were complicated cysts. The mean age of patients with AML was significantly lower than that of patients without AML (61.71 [SD, 13.25] years vs 68.80 [SD, 17.85] years; p = 0.005). There was a female association with AMLs (p < 0.001). CONCLUSION: Echogenic nonshadowing renal lesions larger than 4 mm seen at ultrasound should not be assumed to represent an AML without follow-up because a percentage of renal cell carcinomas will be missed. Although certain ultrasound features can be useful in differentiating an AML from a renal cell carcinoma and CT is frequently diagnostic, an understanding of MRI is important because it can potentially detect lipid-poor AMLs.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2017) conducted an observational in Echogenic nonshadowing renal masses (> 4 mm) (n=132). Echogenic nonshadowing renal lesions > 4 mm on ultrasound was evaluated on Diagnosis of angiomyolipoma. Among echogenic nonshadowing renal lesions >4 mm found at ultrasound, 62.0% were angiomyolipomas and 5.1% were renal cell carcinomas, indicating follow-up is necessary to avoid missing cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: